Teshamae S Monteith, Nemin Chen, Jessica Cirillo, Lucy Abraham, Aaron Jenkins, Phillip Saccone, Chelsea Leroue, Feng Dai, Karina Nakajima, Elizabeth McCaig, Jessica Ailani
{"title":"Healthcare providers' perceptions and prescribing behaviors of short-term prevention treatment of migraine in the United States.","authors":"Teshamae S Monteith, Nemin Chen, Jessica Cirillo, Lucy Abraham, Aaron Jenkins, Phillip Saccone, Chelsea Leroue, Feng Dai, Karina Nakajima, Elizabeth McCaig, Jessica Ailani","doi":"10.1080/17581869.2026.2734046","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Short-term prevention (STP) therapies are used to prevent migraine during anticipated exposure to known triggers. However, little is known about healthcare providers' (HCPs) attitudes and prescribing practices regarding STP. This study aimed to characterize real-world STP treatment perceptions and prescribing behaviors among US HCPs.</p><p><strong>Materials and methods: </strong>US HCPs aware of STP treatment completed a cross-sectional survey (August-September 2024) assessing demographic and practice characteristics, STP perceptions, and patient factors considered when prescribing STP.</p><p><strong>Results: </strong>Over 90% of HCPs agreed that migraine treatment should provide patients with flexibility to control their attacks. Gepants were the most frequently prescribed STP treatment (71.9%), with rimegepant being the most prescribed gepant for STP (84.1%). Menstrual migraine (83.3%) and the ability to predict triggers (78.2%) were the most frequently considered patient characteristics. Primary care providers and nurse practitioners/physician assistants considered a wider array of patient factors than headache specialists and other neurologists.</p><p><strong>Conclusions: </strong>HCPs aware of STP believe patients with migraine, especially those with perimenstrual attacks, may benefit from STP treatment. Gepants were the most prescribed STP migraine treatment.</p>","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"1-9"},"PeriodicalIF":1.7000,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17581869.2026.2734046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Short-term prevention (STP) therapies are used to prevent migraine during anticipated exposure to known triggers. However, little is known about healthcare providers' (HCPs) attitudes and prescribing practices regarding STP. This study aimed to characterize real-world STP treatment perceptions and prescribing behaviors among US HCPs.
Materials and methods: US HCPs aware of STP treatment completed a cross-sectional survey (August-September 2024) assessing demographic and practice characteristics, STP perceptions, and patient factors considered when prescribing STP.
Results: Over 90% of HCPs agreed that migraine treatment should provide patients with flexibility to control their attacks. Gepants were the most frequently prescribed STP treatment (71.9%), with rimegepant being the most prescribed gepant for STP (84.1%). Menstrual migraine (83.3%) and the ability to predict triggers (78.2%) were the most frequently considered patient characteristics. Primary care providers and nurse practitioners/physician assistants considered a wider array of patient factors than headache specialists and other neurologists.
Conclusions: HCPs aware of STP believe patients with migraine, especially those with perimenstrual attacks, may benefit from STP treatment. Gepants were the most prescribed STP migraine treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
